RMP
PFE icon

Richards, Merrill & Peterson’s Pfizer PFE Stock Holding History

Richards, Merrill & Peterson’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,922
Closed -$48.7K – 398
2025
Q1 		$48.7K Hold
1,922
– – 0.03% 256
2024
Q4 		$51K Buy
+1,922
New +$52.1K 0.03% 237

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Richards, Merrill & Peterson's PFE Position: Q2 2025 in Review

Richards, Merrill & Peterson sold out of Pfizer (PFE) in Q2 2025, closing a stake of 1,922 shares — an estimated $48.7K sold.

Richards, Merrill & Peterson first reported a position in PFE in Q4 2024 and held it in 2 quarters. The position peaked at $51K in Q4 2024. 2,810 funds tracked by Wall St. Rank hold PFE as of Q2 2025.

  • Richards, Merrill & Peterson reported no remaining Pfizer position as of Q2 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 1,922 Pfizer shares in Q2 2025, an estimated $48.7K.
  • Richards, Merrill & Peterson first reported a position in Pfizer in Q4 2024 and held it in 2 quarters.
  • Richards, Merrill & Peterson's Pfizer position peaked at $51K in Q4 2024.
  • 2,810 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q2 2025, filed 31 Jul 2025.